Clinical Clearance Following Improvement of Histologic Subtype of Basal Cell Carcinoma with Sonidegib
DOI:
https://doi.org/10.2340/actadv.v102.2740Keywords:
Basal cell carcinoma, sonidegib, Hedgehog pathway inhibitor, locally advanced BCCAbstract
Abstract is missing (Short communication)
Downloads
References
Marzuka AG, Book SE. Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. Yale J Biol Med 2015; 88: 167-179.
Ciążyńska M, Kamińska-Winciorek G, Lange D, Lewandowski B, Reich A, Sławińska M, et al. The incidence and clinical analysis of non-melanoma skin cancer. Sci Rep 2021; 11: 4337. DOI: https://doi.org/10.1038/s41598-021-94435-7
https://doi.org/10.1038/s41598-021-83502-8 DOI: https://doi.org/10.1038/s41598-021-83502-8
Lear JT, Corner C, Dziewulski P, Fife K, Ross GL, Varma S, et al. Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective. Br J Cancer 2014; 111: 1476-1481.
https://doi.org/10.1038/bjc.2014.270 DOI: https://doi.org/10.1038/bjc.2014.270
Dummer R, Guminksi A, Gutzmer R, Lear JT, Lewis KD, Chang ALS, et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br J Dermatol 2020; 182: 1369-1378.
https://doi.org/10.1111/bjd.18552 DOI: https://doi.org/10.1111/bjd.18552
Lear JT, Migden MR, Lewis KD, Chang ALS, Guminski A, Gutzmer R, et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol 2018; 32: 372-381.
https://doi.org/10.1111/jdv.14542 DOI: https://doi.org/10.1111/jdv.14542
Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol 2015; 16: 716-728.
https://doi.org/10.1016/S1470-2045(15)70100-2 DOI: https://doi.org/10.1016/S1470-2045(15)70100-2
Dummer R, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, et al. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol 2016; 75: 113-125.e115.
https://doi.org/10.1016/j.jaad.2016.02.1226 DOI: https://doi.org/10.1016/j.jaad.2016.02.1226
No authors listed. Sonidegib for basal cell carcinoma. Aust Prescr 2018; 41: 94.
https://doi.org/10.18773/austprescr.2018.025 DOI: https://doi.org/10.18773/austprescr.2018.025
Elder D, Massi D, Scolyer R, Willemze R. WHO classification of skin tumors. Lyon: International Agency for Research on Cancer, World Health Organization, International Academy of Pathology; 2018: p. 470.
Dummer R, Lear JT, Guminski A, Leow LJ, Squittieri N, Migden M. Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT) trial at 42 months. J Am Acad Dermatol 2021; 84: 1162-1164.
https://doi.org/10.1016/j.jaad.2020.08.042 DOI: https://doi.org/10.1016/j.jaad.2020.08.042
Migden MR, Chang ALS, Dirix L, Stratigos AJ, Lear JT. Emerging trends in the treatment of advanced basal cell carcinoma. Cancer Treat Rev 2018; 64: 1-10.
https://doi.org/10.1016/j.ctrv.2017.12.009 DOI: https://doi.org/10.1016/j.ctrv.2017.12.009
Gutzmer R, Robert C, Loquai C, Schadendorf D, Squittieri N, Arntz R, et al. Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis. BMC Cancer 2021; 21: 1244.
https://doi.org/10.1186/s12885-021-08968-1 DOI: https://doi.org/10.1186/s12885-021-08968-1
Leow LJ, Teh N. Clinical clearance of complex basal cell carcinoma in patients receiving sonidegib: a case series. Dermatol Ther 2022; 35: e15217.
https://doi.org/10.1111/dth.15217 DOI: https://doi.org/10.1111/dth.15217
Lewis K, Dummer R, Farberg AS, Guminski A, Squittieri N, Migden M. Effects of sonidegib following dose reduction and treatment interruption in patients with advanced basal cell carcinoma during 42-month BOLT trial. Dermatol Ther (Heidelb) 2021; 11: 2225-2234.
https://doi.org/10.1007/s13555-021-00619-4 DOI: https://doi.org/10.1007/s13555-021-00619-4
Teh N, Leow LJ. The role of actin in muscle spasms in a case series of patients with advanced basal cell carcinoma treated with a hedgehog pathway inhibitor. Dermatol Ther (Heidelb) 2021; 11: 293-299.
https://doi.org/10.1007/s13555-020-00464-x DOI: https://doi.org/10.1007/s13555-020-00464-x
Published
How to Cite
License
Copyright (c) 2022 Liang Joo Leow, Vicki Howard
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
